EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

Milan Beljkas, Aleksandra Ilic iD, Alen Cebzan iD, Branko Radovic iD, Nemanja Djokovic iD, Dusan Ruzic iD, Katarina Nikolic iD, Slavica Oljacic

Pharmaceutics · 03.11.2023 · 15 (11) · 2581

DOI: 10.3390/pharmaceutics15112581 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.11.2023. Verfasst von Milan Beljkas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) are the major regulators of the balance of acetylation of histone and non-histone proteins. In contrast to other HDAC isoforms, HDAC6 is mainly involved in maintaining the acetylation balance of many non-histone proteins. Therefore, the overexpression of HDAC6 is associated with tumorigenesis, invasion, migration, survival, apoptosis and growth of various malignancies. As a result, HDAC6 is considered a promising target for cancer treatment. However, none of selective HDAC6 inhibitors are in clinical use, mainly because of the low efficacy and high concentrations used to show anticancer properties, which may lead to off-target effects. Therefore, HDAC6 inhibitors with dual-target capabilities represent a new trend in cancer treatment, aiming to overcome the above problems. In this review, we summarize the advances in tumor treatment with dual-target HDAC6 inhibitors.

Schlagwörter

Stichwörter der Autor:innen

cancerdual-target therapyepigeneticshistone deacetylasesinhibitorskinasesrational design

Autor:innen und Institutionen

  • Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.

ORCID-Profile: Aleksandra Ilic, Alen Cebzan, Branko Radovic, Nemanja Djokovic, Dusan Ruzic, Katarina Nikolic

Förderung

  • Ministry of Science, Technological Development and Innovation, Republic of Serbia

Zitieren

APA

Beljkas, M., Ilic, A., Cebzan, A., Radovic, B., Djokovic, N., Ruzic, D., Nikolic, K., & Oljacic, S. (2023). Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. Pharmaceutics, 15(11), 2581. https://doi.org/10.3390/pharmaceutics15112581

Vancouver

Beljkas M, Ilic A, Cebzan A, Radovic B, Djokovic N, Ruzic D, et al. Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer. Pharmaceutics. 2023;15(11):2581. doi:10.3390/pharmaceutics15112581

BibTeX
@article{Beljkas2023,
  author = {Beljkas, Milan and Ilic, Aleksandra and Cebzan, Alen and Radovic, Branko and Djokovic, Nemanja and Ruzic, Dusan and Nikolic, Katarina and Oljacic, Slavica},
  title = {Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {2581},
  doi = {10.3390/pharmaceutics15112581}
}
Kostenlos starten →